Filtros de búsqueda

Lista de obras de

"Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?"

scientific article published on 18 March 2012

18F-FDG PET/CT in multiple myeloma: critical insights and future directions

artículo científico publicado en 2019

213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma

artículo científico publicado en 2013

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

artículo científico publicado en 2016

A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom Macroglobulinemia

scientific article published on 09 August 2012

A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma

scientific article published on 02 May 2014

A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia

artículo científico publicado en 2020

A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients

artículo científico publicado en 2018

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

artículo científico publicado en 2018

A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma ⬇️

artículo científico publicado en 2017

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

artículo científico publicado en 2017

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

scientific article published on 19 August 2019

ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents

artículo científico publicado en 2011

ABT-737 is highly effective against molecular subgroups of multiple myeloma

artículo científico publicado en 2011

Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide

scientific article published on 28 April 2020

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

artículo científico publicado en 2010

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

scientific article published on 13 October 2009

Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients

artículo científico publicado en 2018

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acu

artículo científico publicado en 2005

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

artículo científico publicado en 2017

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

artículo científico publicado en 2014

All transplantation-eligible patients with myeloma should receive ASCT in first response.

artículo científico publicado en 2014

Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go?

scientific article published on July 2011

Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?

artículo científico publicado en 2009

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.

artículo científico publicado en 2017

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

artículo científico publicado en 2018

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

artículo científico publicado en 2016

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

artículo científico publicado en 2018

Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience ⬇️

artículo científico publicado el 18 de octubre de 2010

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

artículo científico publicado en 2020

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

artículo científico publicado en 2018

Atypical plasma cell leukemia mistaken for lymphocytosis on blood count.

artículo científico publicado en 2015

Autologous hematopoietic stem-cell transplantation for multiple myeloma

artículo científico publicado en 2009

Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma

artículo científico publicado en 2012

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.

artículo científico publicado en 2016

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

artículo científico publicado en 2018

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

scientific article published on 16 December 2019

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.

artículo científico publicado en 2014

Best therapy for primary amyloidosis, a not-yet-solved question

scientific article published on 01 November 2004

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

scientific article published on 18 June 2018

Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.

artículo científico publicado en 2012

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

artículo científico publicado en 2015

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

artículo científico publicado en 2009

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

artículo científico publicado en 2006

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

artículo científico publicado en 2010

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

artículo científico publicado en 2010

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

artículo científico publicado en 2011

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

artículo científico publicado en 2016

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

artículo científico publicado en 2013

Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2014

CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis

artículo científico publicado en 2007

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

artículo científico publicado en 2003

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity

artículo científico publicado en 2005

CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia

artículo científico publicado en 2002

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages

artículo científico publicado en 2019

Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center

artículo científico publicado en 2006

Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply

scientific article published on 29 March 2016

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

scientific article published on 03 May 2019

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

artículo científico publicado en 2015

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

artículo científico publicado en 2017

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

artículo científico publicado en 2017

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

scientific article published on 28 February 2019

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

artículo científico publicado en 2016

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

article

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

artículo científico publicado en 2017

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

artículo científico publicado en 2019

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

artículo científico publicado en 2017

Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.

artículo científico publicado en 2012

Cereblon expression in multiple myeloma: not ready for prime time

artículo científico publicado en 2013

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

artículo científico publicado en 2018

Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1

scientific article published on 15 May 2020

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

scientific article published on 22 August 2019

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

artículo científico publicado en 2013

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation

scientific article published on 29 April 2020

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

artículo científico publicado en 2015

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project

artículo científico publicado en 2018

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

artículo científico publicado en 2014

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

artículo científico publicado en 2002

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma

artículo científico publicado en 2019

Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients

artículo científico publicado en 2016

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis

artículo científico publicado en 2013

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma

artículo científico

Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status

scientific article published on 14 April 2020

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults

artículo científico publicado en 2014

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

artículo científico publicado en 2011

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

artículo científico publicado en 2016

Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience

artículo científico publicado en 2014

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)

artículo científico publicado en 2019

Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma

scientific article published on 23 May 2020

Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial

artículo científico publicado en 2013

Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system ⬇️

artículo científico publicado el 23 de diciembre de 2010

Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.

artículo científico publicado en 2012

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.

artículo científico publicado en 2015

Current treatment landscape for relapsed and/or refractory multiple myeloma

artículo científico publicado en 2014

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

artículo científico publicado en 2011

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

artículo científico publicado en 2015

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial

scientific article published on 19 June 2019

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

artículo científico publicado en 2020

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

artículo científico publicado en 2019

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

scientific article published on 21 May 2019

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

artículo científico publicado en 2020

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

scholarly article by Athanasios Dimopoulos et al published 20 September 2018 in Haematologica

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma

artículo científico publicado en 2016

Deacetylase inhibitors: an advance in myeloma therapy?

artículo científico publicado en 2017

Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients

artículo científico publicado en 2018

Decade in review-haematological cancer: advances in biology and therapy

artículo científico publicado en 2014

Deciphering the chronology of copy number alterations in Multiple Myeloma

artículo científico publicado en 2019

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

artículo científico publicado en 2017

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).

artículo científico publicado en 2017

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

artículo científico publicado en 2005

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

artículo científico publicado en 2019

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma

artículo científico publicado en 2015

Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study

artículo científico publicado en 2020

Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma.

artículo científico publicado en 2004

Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

artículo científico publicado en 2012

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

artículo científico publicado en 2020

Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma

scientific article published on 17 June 2019

Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma

artículo científico publicado en 2012

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

artículo científico publicado en 2009

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

artículo científico publicado en 2017

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2015

Elotuzumab for the treatment of multiple myeloma.

artículo científico publicado en 2014

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

artículo científico publicado en 2015

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

artículo científico publicado en 2012

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2018

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

artículo científico publicado en 2017

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

artículo científico publicado en 2019

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

artículo científico publicado en 2016

European perspective on multiple myeloma treatment strategies in 2014

artículo científico publicado en 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses

artículo científico publicado en 2012

Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients

artículo científico publicado en 2013

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

artículo científico publicado en 2019

Extramedullary disease in multiple myeloma: a systematic literature review

artículo científico publicado en 2022

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?

artículo científico publicado en 2020

FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma

artículo científico publicado en 2008

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

artículo científico publicado en 2017

First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

scientific article published on 22 January 2020

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

artículo científico publicado en 2011

Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies

scientific article published on 03 May 2011

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

artículo científico publicado en 2014

Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation

artículo científico

Frontline therapy of multiple myeloma.

artículo científico

Frontline treatment of multiple myeloma in elderly patients

artículo científico publicado en 2008

Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study

artículo científico publicado en 2017

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

artículo científico publicado en 2007

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

scientific article published on 23 August 2019

Genomic patterns of progression in smoldering multiple myeloma

scientific article published in Nature Communications

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials

artículo científico publicado en 2020

Good clinical practice recommendations for the use of PET/CT in oncology

scientific article published on 21 October 2019

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

artículo científico publicado en 2016

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

artículo científico publicado en 2014

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

article

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

artículo científico publicado en 2020

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

scientific article published on 09 April 2020

Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma

scientific article published on 29 May 2018

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

artículo científico publicado en 2017

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

artículo científico publicado en 2014

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

article by Arnaud Jaccard et al published 13 September 2007 in The New England Journal of Medicine

High-dose chemotherapy followed by autologous stem-cell transplantation in liver-transplanted multiple myeloma patients: a report of two cases

artículo científico publicado en 2009

High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma

artículo científico publicado en 2005

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Tr

artículo científico publicado en 2016

How I treat extramedullary myeloma

artículo científico

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

artículo científico publicado en 2017

How to manage neutropenia in multiple myeloma

artículo científico

Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults

artículo científico publicado en 2014

IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop

artículo científico publicado en 2008

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

scientific article published on 08 June 2018

IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.

artículo científico publicado en 2014

IgM myeloma: A multicenter retrospective study of 134 patients

artículo científico publicado en 2017

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma

scientific article published on 19 February 2020

ImmunoPET in Multiple Myeloma-What? So What? Now What?

artículo científico publicado en 2020

Immunophenotype of normal and myelomatous plasma-cell subsets

artículo científico

Impact of Graft-Versus-Graft Natural Killer Cell Alloreactivity on Single Unit Dominance After Double Umbilical Cord Blood Transplantation

artículo científico publicado en 2016

Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.

artículo científico publicado en 2009

Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire

artículo científico publicado en 2011

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

artículo científico publicado en 2017

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

artículo científico publicado en 2015

Increased plasmacytoid dendritic cells and RORγt-expressing immune effectors in cutaneous acute graft-versus-host disease

artículo científico publicado en 2013

Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies

artículo científico publicado en 2009

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies

artículo científico publicado en 2019

Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation

artículo científico publicado en 2014

Insights on Multiple Myeloma Treatment Strategies

artículo científico publicado en 2018

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

artículo científico publicado en 2020

Interest of Pet Imaging in Multiple Myeloma

scientific article published in 2019

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study

artículo científico publicado en 2018

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

artículo científico publicado en 2016

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

artículo científico publicado en 2014

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

artículo científico publicado en 2010

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

scientific article published on 09 November 2018

Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma

artículo científico publicado en 2008

Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study

artículo científico publicado en 2012

Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?

artículo científico publicado en 2012

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

artículo científico publicado en 2017

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

scientific article published on 13 December 2019

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

scientific article published on 23 May 2020

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

artículo científico publicado en 2019

Ixazomib in the management of relapsed multiple myeloma.

artículo científico publicado en 2018

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

artículo científico publicado en 2017

Lack of CD27 in myeloma delineates different presentation and outcome

scientific article published on 01 January 2006

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation

artículo científico publicado en 2016

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

artículo científico publicado en 2017

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

artículo científico publicado en 2012

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

artículo científico publicado en 2014

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

artículo científico publicado en 2010

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Lenalidomide: a new therapy for multiple myeloma

artículo científico publicado en 2008

Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis

scientific article published on 29 June 2019

Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.

artículo científico publicado en 2004

Logic programming reveals alteration of key transcription factors in multiple myeloma

artículo científico publicado en 2017

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

artículo científico publicado en 2018

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

artículo científico publicado en 2012

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

artículo científico publicado en 2010

Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma

scientific article published on 01 November 2008

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

article

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.

artículo científico publicado en 2013

MRD in multiple myeloma: more questions than answers?

artículo científico publicado en 2017

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

artículo científico publicado en 2018

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

scientific article published on 27 July 2006

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2017

Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study ⬇️

artículo científico publicado el 1 de febrero de 2011

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

artículo científico publicado en 2016

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

artículo científico publicado en 2006

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial

artículo científico publicado en 2013

Multiple myeloma--translation of trial results into reality

artículo científico publicado en 2016

Multiple myeloma: so much progress, but so many unsolved questions

artículo científico publicado en 2013

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

artículo científico publicado en 2010

New developments in conditioning regimens before auto-SCT in multiple myeloma ⬇️

artículo científico publicado el 28 de febrero de 2011

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib

artículo científico

New insights in the treatment of patients with solitary bone plasmacytoma

artículo científico publicado en 2019

Newly Diagnosed Myeloma in 2020

scientific article published on 01 March 2020

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

artículo científico publicado en 2018

Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

scientific article published on 28 February 2020

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel

artículo científico publicado en 2010

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

artículo científico publicado en 2019

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

artículo científico publicado en 2018

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials

artículo científico publicado en 2019

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

artículo científico publicado en 2016

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients

scientific article published on 18 February 2017

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

artículo científico publicado en 2014

Panobinostat for the Treatment of Multiple Myeloma.

artículo científico

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes

artículo científico publicado en 2015

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

artículo científico publicado en 2015

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

artículo científico publicado en 2014

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.

artículo científico publicado en 2017

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

artículo científico

Paraneoplastic cutaneous leukocytoclastic vasculitis disclosing multiple myeloma: a case report

artículo científico publicado en 2011

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

artículo científico

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2018

Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.

artículo científico publicado en 2004

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

scientific article published on 15 May 2019

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

artículo científico publicado en 2010

Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma

artículo científico publicado en 2012

Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma

artículo científico

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

artículo científico publicado en 2016

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

artículo científico publicado en 2014

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

artículo científico publicado en 2015

Pomalidomide in the management of relapsed multiple myeloma

artículo científico publicado en 2016

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

artículo científico publicado en 2015

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

artículo científico publicado en 2016

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

artículo científico publicado en 2013

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

artículo científico publicado en 2013

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

artículo científico publicado en 2020

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2018

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study

artículo científico publicado en 2019

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

artículo científico publicado en 2016

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

artículo científico publicado en 2013

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

article

Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients

artículo científico publicado en 2012

Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: Data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003-2016).

artículo científico publicado en 2017

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry ⬇️

artículo científico publicado el 1 de julio de 1997

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

artículo científico publicado en 2010

Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).

artículo científico publicado en 2013

Prognostic role of circulating exosomal miRNAs in multiple myeloma

artículo científico publicado en 2017

Prognostic significance of copy-number alterations in multiple myeloma

artículo científico publicado en 2009

Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life

artículo científico publicado en 2020

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

artículo científico publicado en 2017

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

artículo científico publicado en 2017

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

artículo científico publicado en 2006

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

artículo científico publicado en 2008

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

scientific article published on 14 May 2019

Proteasome inhibitors in multiple myeloma: 10 years later

artículo científico

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

artículo científico publicado en 2003

Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

artículo científico publicado en 2016

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.

artículo científico publicado en 2014

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

artículo científico publicado en 2017

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

artículo científico publicado en 2016

Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.

artículo científico publicado en 2017

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

artículo científico publicado en 2018

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

scientific article published on 01 September 2002

Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.

artículo científico publicado en 2010

Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial

artículo científico publicado en 2014

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).

artículo científico publicado en 2016

Report of the 6th International Workshop on PET in lymphoma

artículo científico publicado en 2017

Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis

artículo científico publicado en 2016

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASP

artículo científico publicado en 2018

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements

scientific article published on 20 December 2018

Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial

artículo científico publicado en 2014

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide

artículo científico publicado en 2018

Rituximab-based first line treatment for chronic GVHD after allogeneic SCT: results of a phase 2 study

artículo científico

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

artículo científico publicado en 2017

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

artículo científico publicado en 2015

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

artículo científico publicado en 2015

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

artículo científico publicado en 2016

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

artículo científico publicado en 2018

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

artículo científico publicado en 2016

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Severe chronic primary neutropenia in adults: report on a series of 108 patients

artículo científico publicado en 2015

Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients

artículo científico publicado en 2016

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

artículo científico publicado en 2019

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

artículo científico publicado en 2020

Stem cell transplantation in multiple myeloma

artículo científico publicado en 2007

Stem-cell transplantation in multiple myeloma

artículo científico publicado en 2005

Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma

scientific article published on 14 February 2014

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

artículo científico publicado en 2020

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

scientific article published on 03 July 2019

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases.

artículo científico publicado en 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

artículo científico publicado en 2011

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

artículo científico publicado en 2015

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

scientific article published on 23 March 2020

Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient

artículo científico publicado en 2016

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

artículo científico publicado en 2012

Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life

artículo científico publicado en 2018

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

scientific article published on 06 September 2005

Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study

artículo científico publicado en 2002

Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

artículo científico publicado en 2020

Targeting Bcl-2 for the treatment of multiple myeloma

artículo científico publicado en 2018

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

artículo científico publicado en 2011

Thalidomide for treatment of multiple myeloma: 10 years later

artículo científico publicado en 2008

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

artículo científico publicado en 2002

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma

scientific article published on 29 August 2019

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective

artículo científico publicado en 2016

The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis?

scientific article published on 03 April 2019

The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.

artículo científico publicado en 2007

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma

scientific article published on 10 June 2019

The effects of bortezomib on bone disease in patients with multiple myeloma

artículo científico publicado en 2013

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

artículo científico

The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients

artículo científico publicado en 2011

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy

artículo científico publicado en 2006

The role of SLAMF7 in multiple myeloma: impact on therapy

artículo científico publicado en 2016

The translocation t(4;14) can be present only in minor subclones in multiple myeloma

artículo científico publicado en 2013

Timing the initiation of multiple myeloma

scientific article published on 21 April 2020

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

artículo científico publicado en 2010

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

scholarly article by Philippe Moreau et al published 20 March 2019 in Blood Cancer Journal

Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials

artículo científico publicado en 2017

Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

artículo científico publicado en 2015

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective

scientific article published on 18 July 2019

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

artículo científico publicado en 2012

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study

artículo científico

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

artículo científico publicado en 2016

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways

artículo científico publicado en 2018

Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required

artículo científico publicado en 2005

[Update of the recommendations of good clinical practice for the use of PET in oncology]

scientific article published on 23 January 2019

c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma

scientific article published on 07 March 2020

p53 regulates CD46 expression and measles virus infection in myeloma cells

scientific article published on 01 December 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda